Coagulation Analyzer Market is expected to reach US$ 6,690.08 million by 2030

Clinical Laboratory Analyzers Segment to Account for Largest Share in Coagulation Analyzers Market During 2022–2030

According to our latest study on Coagulation Analyzers Market Forecast to 2030 – COVID-19 Impact and Global Analysis – by Product Type, Test Type, Technology, and Application," the market is expected to grow from US$ 4,183.71 million in 2022 to US$ 6,690.08 million by 2030; it is expected to register a CAGR of 6.0% from 2022 to 2030. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

Global Coagulation Analyzers Market, by Region, 2022 (%)

Source: The Insight Partners Analysis

Increasing Organic and Inorganic Strategies by Key Players Provides Lucrative Market Opportunities

In recent years, changing lifestyle habits and growing geriatric population are increasing the incidence of various types of blood disorders. Thus, there is an increasing demand for early diagnosis and treatment of blood disorders. To enhance the quality of life of people suffering from hemorrhagic disease, key players are taking several initiatives through various organic and inorganic strategies.

• In 2019, Nihon Kohden announced the plan to establish a hematology analyzer reagent factory in Dubai.
• In October 2021, Trivitron Healthcare, a medical devices company, launched a new line of coagulation analyzer products manufactured by Diagon Ltd in India.
• In June 2021, Trivitron Healthcare introduced NANO H5 and NANO H110 that monitor diabetes, thalassemia, and hemoglobin variations.
• In February 2021, Siemens Healthineers and Sysmex Corporation renewed their long-standing agreement for the global supply, distribution, sales, and service of hemostasis products, which included an extension for multiple years. Further, Siemens Healthineers will distribute Sysmex's automated blood coagulation analyzer, including the CN-3000 and CN-6000, as part of their agreement. Laboratories are provided with these machines, the next generation of fully automated coagulation testing solutions.
• In July 2020, Sysmex Corporation launched the Automated Blood Coagulation Analyzers CN-6500/CN-3500 in Japan. In addition to the blood coagulation and platelet aggregation parameters, it also measures thrombosis and hemostasis parameters.
• In February 2018, Horiba, a Japanese manufacturer of precision instruments for measurement and analysis, launched the Yumizen G, a range of semiautomatic to fully automatic hemostasis solutions for clinical testing.
• In May 2018, Beckman Coulter company launched the DxH 900 hematology analyzer, which performs complete blood count and differential white blood cell tests with minimal repeats for use in mid- to high-volume clinical laboratories.

Thus, various organic and inorganic strategies adopted by the key market players are anticipated to provide additional opportunities for the growth of the coagulation analyzer market during the forecast period.

The European coagulation analyzers market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global coagulation analyzers market and is estimated to register a robust growth rate during the forecast period. The factors driving the growth of the market in the region are rising cardiovascular disorders, increasing advancements in medical devices, growing aging population, and rising awareness about coagulation analyzers.

Germany is among the countries with a high number of patients suffering from cardiovascular disorders. Also, the growing aging population is accelerating the number of cardiovascular disorders in the country. In Germany, heart attack is the most serious consequence of coronary heart disease (CHD). More than 3.6 million people have been diagnosed with CHD, and over 1.3 million have survived a stroke. According to the latest WHO data published in 2020, CHD deaths in Germany reached 147,055 (i.e., 20.98%) of total deaths. Similarly, heart diseases are prevalent in the UK. As per the British Heart Foundation January 2021 report, ~7.6 million people in the UK were diagnosed with heart and circulatory diseases. Heart and circulatory diseases cause more than 27% of all deaths in the UK. In addition, CVDs incur an estimated cost of US$ 25 billion each year to the UK economy. In 2019, the mortality rate from CVD in the UK was 255 deaths per 100,000 people. In France, the geriatric population is increasing exponentially. According to the French Institute for Demographic Studies or INED, the aging population in France is expected to increase 90% during 2030–2050. The growing aging population is prone to cardiac diseases and other abnormalities such as arrhythmia and myocardial infarction. Thus, there is an increasing demand for various diagnosing equipment, such as coagulation analyzers.

According to the latest WHO data published in 2020, coronary heart disease deaths in Spain reached 51,684 (i.e., 15.64%) of total deaths. According to Statista, in 2020, Spain had a mortality rate from ischemic heart disease of around 55.59 deaths per 100,000 inhabitants. The increasing prevalence of blood disorders in the region is also likely to increase the demand for coagulation analyzers. As per the Haemophilia Society, von Willebrand disorder (VWD) affected 7,071 women and 4,081 men in the UK, while Hemophilia A affected ~8,740 people in the UK. Further, according to the European Haemophilia Consortium (EHC), in 2019, an international non-profit organization, ~90,000 people were diagnosed with rare bleeding conditions such as hemophilia and von Willebrand Disease (VWD) in Europe. The rising mortality of haemophilia A and associated blood disorders is likely to accelerate the demand for coagulation analyzers during 2022–2030.

Abbott Laboratories, Danaher Corp, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc, Sysmex Corporation, Horiba Ltd., Nihon Kohden Corp, F. Hoffmann-La Roche Ltd, Maccura Biotechnology Co Ltd, and Bio Group Medical System SRL are among the leading companies operating in the global coagulation analyzers market.

Various organic and inorganic strategies are adopted by companies operating in the global coagulation analyzers market. Organic strategies mainly include product launches and product approvals. Further, acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players operating in the global coagulation analyzers market are listed below.

• In February 2021, Siemens Healthineers and Sysmex Corporation announced the renewal of the companies' long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis products including a multi-year extension. As part of the agreement, Siemens Healthineers will distribute the new Sysmex CN Systems.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com